prasugrel

(Newser) - Novartis AG will pay a San Francisco biopharmaceutical company $75 million—with the potential for an additional $500 million—for the worldwide rights to an experimental anticlotting drug the Swiss drug firm hopes will rival Plavix, reports the Wall Street Journal. Market leader Plavix rang up $8.22 billion in...

(Newser) - An experimental new blood-thinner looks like real competition for top-selling anti-clotting drug Plavix, after proving more effective at preventing heart attacks, strokes, and heart-related death in a recent trial, the AP reports. But “there is a price to pay” for increased effectiveness, wrote one doctor—the new drug caused...